-transparent.png){kind=logo}
OBJECTIVE This study was designed to examine the effects of captopril on the coronary vascular responses to nitroglycerin. BACKGROUND The vasodilator effects of nitroglycerin are mediated by sulfhydryl-dependent bioconversion and influenced by local and systemic neural and hormonal counter-regulatory factors. METHODS In patients with angina pectoris, the effects of 10 days of treatment with the sulfhydryl-containing angiotensin-converting enzyme inhibitor captopril on the coronary vasodilator responses to intracoronary nitroglycerin (1- to 20-micrograms doses) were examined utilizing a double-blind, placebo-controlled, randomized design. The effects of captopril on the induction of nitroglycerin tolerance were also examined after a 20-h intravenous infusion of nitroglycerin. RESULTS Captopril reduced mean arterial pressure at rest by 8 mm Hg compared with 3 mm Hg in the placebo group (p = NS) and did not affect baseline coronary blood flow (168 vs. 144 ml/min in the placebo group, standard error of the differences of means (SED) 26) or coronary vascular resistance (53 vs. 57 dynes.s.cm-5, SED 9). Intracoronary nitroglycerin increased coronary blood flow in a dose-dependent fashion in both the captopril and placebo groups (p < 0.001). However, captopril potentiated the effects of all doses of nitroglycerin and shifted the dose-response relationship to the left (p < 0.001). At the maximal dose of 20 micrograms, intracoronary nitroglycerin increased the coronary blood flow by a further 60% in the captopril group compared with placebo. After 20 h of intravenous nitroglycerin (24 +/- 3 micrograms/min), the coronary vasodilator responses to intracoronary nitroglycerin were attenuated (p < 0.02) in the placebo group. However, the responses to intracoronary nitroglycerin in the captopril group, remained similar to the responses observed before intravenous nitroglycerin exposure. CONCLUSIONS Captopril potentiates the coronary vasodilator responses of nitroglycerin in both the absence and the presence of nitroglycerin tolerance. The mechanisms and therapeutic implications of this interaction require further exploration.
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
December 1983,
Presse medicale (Paris, France : 1983),
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
January 1997,
Peptides,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
July 1990,
The American journal of cardiology,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
November 1989,
Circulation research,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
July 1991,
The Journal of pharmacology and experimental therapeutics,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
April 1966,
Die Medizinische Welt,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
December 1997,
Clinical cardiology,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
January 1972,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
March 1962,
Circulation research,
I T Meredith, and
J F Alison, and
F M Zhang, and
J D Horowitz, and
R W Harper
January 1983,
Acta medica Scandinavica. Supplementum,
